Boehringer has launched Pexion, a novel anti-epileptic tablet for dogs that contains the active ingredient imepitoin. This is the first new molecule for this disease area in years.
A new treatment for canine idiopathic epilepsy has been launched by Boehringer Ingelheim Vetmedica. Pexion is a novel anti-epileptic tablet for dogs that contains the active ingredient imepitoin. This is the first new molecule for this disease area in a number of years.
According to the company, Pexion has a highly targeted mode of action to specifically suppress a dog’s seizures. It starts to work within a few hours and reaches steady state within three days, making it easier to rapidly stabilise epileptic patients.
In addition, there is no evidence of hepatotoxicity or liver-associated enzyme elevation, so repeated blood tests for liver enzymes or therapeutic levels are no longer required.
Pexion is available in 100mg and 400mg tablets. The tablets are white, scored and divisible in half. Both tablet strengths are available in 100 tablet packs from veterinary wholesalers.
Canine epilepsy can affect up to 5% of dogs. In most dogs diagnosed with idiopathic epilepsy no underlying cause for the seizures can be found. While the condition can affect any dog, it is more common in young purebred dogs such as Labradors, golden retrievers, German shepherds, boxers, vizlas, beagles, English springer spaniels, Irish setters, poodles and dachshunds.
Jemima Mead, brand manager at Boehringer, said: “Pexion is a ground-breaking new product that gives vets a new first-line treatment option for dogs with idiopathic epilepsy, improving the lives of newly diagnosed epileptic dogs and their owners by reducing the number of seizures and their impact on the patient’s life.”